Negative expression of CD117 predicted inferior OS and PFS in acute promyelocytic leukemia
International Journal of Laboratory Hematology · 2024-12 · 46 (6) · 1052-1058
DOI: 10.1111/ijlh.14326 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, online erschienen am 14.06.2024. Verfasst von Hui Zeng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Proto-Oncogene Proteins c-kit. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
In recent years, the correlation between CD117 antigen and the prognosis of hematological malignancies has been demonstrated. However, there is limited literature on the clinical significance of CD117 antigen in acute promyelocytic leukemia (APL). The aim of this study was to retrospectively analyze the clinical features and prognostic significance of CD117 in APL.
Methods
In this study, we retrospectively investigated the clinicopathological characteristics, outcome, and prognostic impact of negative CD117 expression (CD117 − ) in 169 APL patients treated with all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) containing regimen.
Results
The median follow‐up period was 63.0 months. CD117 − was detected in 13 APL patients (7.7%). No significant differences were found in baseline characteristics between CD117+ and CD117 − subgroups. However, compared to CD117+ APL, the incidence of early death (ED) was significantly higher in CD117 − APL ( p = 0.023). By multivariate analysis, CD117‐ was an independent adverse prognostic factor for overall survival (OS) and progression‐free survival (PFS) ( p = 0.022 and p = 0.014, respectively).
Conclusions
To sum up, CD117 − is associated with greater risk of ED and has the statistical power to predict inferior OS and PFS, this marker may be considered to build prognostic scores for risk‐adapted therapeutic strategies in APL management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
ORCID-Profile: Yu Ben
Zitieren
APA
Zeng, H., He, J., Dong, H. B., Zhou, M., Zhang, Q., Chen, L. X., Yuan, C. Y., Jiang, R. R., Liu, J. W., Ou-Yang, J., Ben, Y., & Chen, B. (2024). Negative expression of CD117 predicted inferior OS and PFS in acute promyelocytic leukemia. International Journal of Laboratory Hematology, 46(6), 1052-1058. https://doi.org/10.1111/ijlh.14326
Vancouver
Zeng H, He J, Dong HB, Zhou M, Zhang Q, Chen LX, et al. Negative expression of CD117 predicted inferior OS and PFS in acute promyelocytic leukemia. International Journal of Laboratory Hematology. 2024;46(6):1052-1058. doi:10.1111/ijlh.14326
BibTeX
@article{Zeng2024,
author = {Zeng, Hui and He, Jie and Dong, Hai-Bo and Zhou, Min and Zhang, Qian and Chen, Lan-Xin and Yuan, Cui-Ying and Jiang, Ru-Ru and Liu, Jin-Wen and Ou-Yang, Jian and Ben, Yu and Chen, Bing},
title = {Negative expression of CD117 predicted inferior OS and PFS in acute promyelocytic leukemia},
journal = {International Journal of Laboratory Hematology},
year = {2024},
volume = {46},
number = {6},
pages = {1052--1058},
doi = {10.1111/ijlh.14326}
}
EUVIMED